Trametinib: all 183 studies that test it
Page 1 of 2. Open to participants first (30), then studies with results posted, then the rest; newest registration first within each.
- Pulsed Stereotactic Ablative Radiotherapy (PULSAR) With Systematic Therapy for Thyroid CancerNot yet recruitingNCT07886905Phase 2
- Clinical Trial of a MEK Inhibitor for RASopathy-Associated Severe Infantile Hypertrophic Cardiomyopathy: Baby MERITNot yet recruitingNCT07817186Phase 3
- 24VA021; VATCH Trametinib for Ras/MAPK Pathway VAsRecruitingNCT07549646Phase 2
- A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With OsteosarcomaRecruitingNCT07477457Phase 2
- DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.RecruitingNCT07440290Phase 2/3
- MRD-positive AML Clinical StudyRecruitingNCT07131059Not applicable
- Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade GliomasRecruitingNCT07110246Phase 2
- Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort StudyNot yet recruitingNCT07010393Phase 4
- Imatinib and Trametinib for KRAS-mutated Solid TumorRecruitingNCT06962254Phase 1
- Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment ExhaustionRecruitingNCT06739395Phase 2
- MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric GliomasRecruitingNCT06712875Phase 1/2
- Clinical Study of Neoadjuvant Targeted Therapy for AmeloblastomaRecruitingNCT06653517Phase 2
- Targeted Approach to Langerhans Cell Histiocytosis (LCH) Using MEK Inhibitor, TrametinibRecruitingNCT06582745Phase 2
- Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.RecruitingNCT06563999Phase 2
- MEK Inhibitors for the Treatment of Hypertrophic Cardiomyopathy in Patients With RASopathiesRecruitingNCT06555237Phase 2
- Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLCNot yet recruitingNCT06456138Phase 1/2
- Precision Cancer Therapy in Rare CancersRecruitingNCT06119789Phase 2
- Dabrafenib Plus Trametinib in Patients With Advanced Solid Tumor Having BRAF V600E Mutation or Clinically Actionable BRAF Gene AlterationsRecruitingNCT05876806Phase 2
- Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated CholangiocarcinomaRecruitingNCT05874414Phase 1/2
- HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological MalignanciesRecruitingNCT05658640Phase 1/2
- XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 MutationNot yet recruitingNCT05275374Phase 1/2
- Pediatric Low Grade Glioma - MEKinhibitor TRIal vs ChemotherapyRecruitingNCT05180825Phase 2
- The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer DrugsRecruitingNCT05159245Phase 2
- Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)RecruitingNCT04485559Phase 1
- Study of Trametinib and Ruxolitinib in Colorectal Cancer and Pancreatic AdenocarcinomaRecruitingNCT04303403Phase 1
- A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.RecruitingNCT04116541Phase 2
- Combination of Alpelisib and Trametinib in Progressive Refractory MeningiomasRecruitingNCT03631953Phase 1
- Melanoma Metastasized to the Brain and SteroidsRecruitingNCT03563729Phase 2
- Dabrafenib and/or Trametinib Rollover StudyRecruitingNCT03340506Phase 4
- The Drug Rediscovery Protocol (DRUP Trial)RecruitingNCT02925234Phase 2
- Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid CancerActive, not recruitingNCT04940052Phase 3Results posted
- Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC).TerminatedNCT04566133Phase 2Results posted
- Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic SyndromeCompletedNCT04487106Phase 2Results posted
- A Study of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSCLCCompletedNCT04452877Phase 2Results posted
- Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D MelanomaTerminatedNCT04310397Phase 2Results posted
- Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung CancerCompletedNCT03704688Phase 1/2Results posted
- Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related OutcomesCompletedNCT03551626Phase 3Results posted
- Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon CancerCompletedNCT03428126Phase 2Results posted
- An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has SpreadCompletedNCT03377361Phase 1/2Results posted
- Pembrolizumab and Trametinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer and KRAS Gene MutationsCompletedNCT03299088Phase 1Results posted
- INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors.TerminatedNCT03272464Phase 1Results posted
- Trametinib in Patients With Advanced Neurofibromatosis Type 1 (NF1)-Mutant Non-small Cell Lung CancerTerminatedNCT03232892Phase 2Results posted
- Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic LeukemiaActive, not recruitingNCT03190915Phase 2Results posted
- Trametinib in Treating Patients With Epithelioid Hemangioendothelioma That is Metastatic, Locally Advanced, or Cannot Be Removed by SurgeryCompletedNCT03148275Phase 2Results posted
- A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to ErlotinibCompletedNCT03076164Phase 1/2Results posted
- Concurrent Dabrafenib + Trametinib With Sterotactic Radiation in BRAF Mutation-Positive Malignant Melanoma and Brain MetastasesTerminatedNCT02974803Phase 2Results posted
- Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III MelanomaActive, not recruitingNCT02858921Phase 2Results posted
- Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG TumorsCompletedNCT02684058Phase 2Results posted
- Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung CancerActive, not recruitingNCT02642042Phase 2Results posted
- Dabrafenib and Trametinib in Treating Patients With BRAF Mutated AmeloblastomaCompletedNCT02367859Phase 2Results posted
- Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or TrametinibTerminatedNCT02314143Phase 2Results posted
- Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 MutationsCompletedNCT02296112Phase 2Results posted
- Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryTerminatedNCT02097225Phase 1Results posted
- Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive MelanomaCompletedNCT02083354Phase 2Results posted
- Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid TumorsActive, not recruitingNCT02079740Phase 1/2Results posted
- Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by SurgeryCompletedNCT02042443Phase 2Results posted
- Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the BrainCompletedNCT02039947Phase 2Results posted
- Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare CancersCompletedNCT02034110Phase 2Results posted
- Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT01989598Phase 2Results posted
- Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and MetabolitesTerminatedNCT01978236Phase 2Results posted
- Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast CancerCompletedNCT01964924Phase 2Results posted
- GSK1120212+GSK2141795 for Cervical CancerTerminatedNCT01958112Phase 2Results posted
- A Phase IIa Study of the MEK Inhibitor Trametinib Monotherapy in the Treatment of Biliary Tract CancersCompletedNCT01943864Phase 2Results posted
- Trametinib With GSK2141795 in BRAF Wild-type MelanomaCompletedNCT01941927Phase 2Results posted
- Japan PhI/II of GSK2118436 and GSK1120212 Combination in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) or Cutaneous Melanoma (Phase II Part)CompletedNCT01928940Phase 2Results posted
- Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid LeukemiaTerminatedNCT01907815Phase 2Results posted
- MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene VariationsCompletedNCT01827384Phase 2Results posted
- BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)CompletedNCT01750918Phase 1/2Results posted
- Dabrafenib With or Without Trametinib in Treating Patients With Advanced Differentiated Thyroid CancerCompletedNCT01723202Phase 2Results posted
- Dabrafenib and Trametinib With Radiosurgery in Melanoma Brain MetsTerminatedNCT01721603Phase 2Results posted
- Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By SurgeryTerminatedNCT01701037Phase 2Results posted
- Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD).CompletedNCT01682083Phase 3Results posted
- An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF InhibitorCompletedNCT01619774Phase 2Results posted
- Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous MelanomaCompletedNCT01597908Phase 3Results posted
- A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant MelanomaCompletedNCT01584648Phase 3Results posted
- GSK1120212 in Surgically Resectable Oral Cavity Squamous Cell CancerCompletedNCT01553851Phase 2Results posted
- GSK1120212 Rollover StudyTerminatedNCT01376310Phase 2Results posted
- An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung CancerCompletedNCT01362296Phase 2Results posted
- Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.CompletedNCT01336634Phase 2Results posted
- GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive MelanomaCompletedNCT01245062Phase 3Results posted
- Study of GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Metastatic Pancreatic CancerCompletedNCT01231581Phase 2Results posted
- Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212CompletedNCT01072175Phase 2Results posted
- Study to Determine the Effectiveness of GSK1120212 in BRAF Mutation-positive Melanoma Previously Treated With or Without a BRAF InhibitorCompletedNCT01037127Phase 2Results posted
- Open-label Study to Evaluate the Safety, PK, and PD of MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory LeukemiasCompletedNCT00920140Phase 2Results posted
- Trametinib Treatment for Complicated Vascular AnomaliesActive, not recruitingNCT07072403Phase 1/2
- Pilot Study on Trametinib for Surgical Unruptured AVMsWithdrawnNCT06098872Phase 2
- A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X MutationsActive, not recruitingNCT05907304Phase 1
- Testing the Safety and Effectiveness of Combining Two Drugs, PLX2853 and Trametinib in the Treatment of Advanced Uveal MelanomaWithdrawnNCT05677373Phase 1/2
- Topical Mitogenic-Activated Protein Kinase (MAPK) Inhibition in RosaceaCompletedNCT05616923Phase 1
- PaTcH Study: A Phase 2 Study of Trametinib and Hydroxychloroquine in Patients With Metastatic Refractory Pancreatic CancerTerminatedNCT05518110Phase 2
- Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal AdenocarcinomaCompletedNCT05440942Phase 1
- Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping MutationTerminatedNCT05435846Phase 1
- "Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR)"WithdrawnNCT05299580Phase 2
- Trametinib Plus Anlotinib in Non-G12C KRAS-Mutant NSCLC PatientsCompletedNCT04967079Phase 1
- Optimization of the Time and Dosage of Trametinib in BRAF Negative Juvenile PatientsActive, not recruitingNCT04943224Phase 2
- Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot StudyTerminatedNCT04801966Not applicable
- Dabrafenib and Trametinib Combination as a Neoadjuvant Strategy in BRAF-positive Anaplastic Thyroid CancerWithdrawnNCT04739566Phase 2
- Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid CancerActive, not recruitingNCT04675710Phase 2
- Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic MelanomaActive, not recruitingNCT04417621Phase 2
- Trial of Safety, Tolerability and Efficacy of Trametinib (SNR1611) in Patients With Amyotrophic Lateral Sclerosis (ALS)TerminatedNCT04326283Phase 1/2